Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Multiple Sclerosis

  Free Subscription


1 BMC Neurol
2 J Neurol
2 PLoS One
2 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Neurol

  1. SAUDER T, Hansen S, Bauswein C, Muller R, et al
    Mindfulness training during brief periods of hospitalization in multiple sclerosis (MS): beneficial alterations in fatigue and the mediating role of depression.
    BMC Neurol. 2021;21:390.
    PubMed         Abstract available

    J Neurol

  2. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    PubMed         Abstract available

  3. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    PubMed         Abstract available

    PLoS One

  4. MECA-LALLANA JE, Oreja-Guevara C, Munoz D, Olascoaga J, et al
    Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    PLoS One. 2021;16:e0258437.
    PubMed         Abstract available

  5. STERNBACH S, West N, Singhal NK, Clements R, et al
    The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation.
    PLoS One. 2021;16:e0250486.
    PubMed         Abstract available

    Rev Neurol (Paris)

  6. LEVY G, Engelhardt E
    Is the unstable ataxic hand of Alajouanine and Akerman a distinct contribution?
    Rev Neurol (Paris). 2021;177:852-858.
    PubMed         Abstract available

  7. PANTAZOU V, Du Pasquier R, Pot C, Le Goff G, et al
    Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a "common" first line treatment.
    Rev Neurol (Paris). 2021;177:935-940.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.